Prospects for developing an effective vaccine against ocular herpes simplex virus infection.
One of the hallmarks of herpes simplex virus (HSV) infection is the establishment of a lifelong latent infection accompanied by periods of recurrent disease. Primary HSV infections or repeated clinical recurrences do not elicit immune responses capable of completely preventing recurrences of endogenous virus. It is therefore questionable if vaccination approaches that seek to mimic the immune response to natural infection will reduce infection or disease due to an exogenous viral challenge. Approaches to the induction of protective responses by altering or enhancing both innate and adaptive immunity, using novel vaccines specifically tested in models of HSV infections of the eye, such as recombinant viral vaccine vectors and DNA vaccines, are detailed in this review.
Koelle
David M
DM
Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ghiasi
Homayon
H
D000818:Animals; D005822:Genetic Vectors; D006801:Humans; D016849:Keratitis, Herpetic / Q000517:prevention & control*; D013678:Technology, Pharmaceutical; D019444:Vaccines, DNA / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use*
D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014765:Viral Vaccines